leisure time -WSS

leisure time

author：leisure time 2025-10-02 00:24:19 - browse：4282

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： 5 important ways Henrietta Lacks changed medical science

focus

WSS

STAT Readout Newsletter: Today's biggest biotech updates

Mega Millions pot grows to $1.25 billion after no winner

STAT Summit: GSK CEO on pharma giant's new direction

Lawmakers consider Medicare pay reforms for doctors

Why health workers in Gaza are injured or die at high rates

‘Oppenheimer’ and the risks of AI in health care

hotspot

leisure time

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What to expect as Trump is arraigned on his Jan 6. indictment

BioMarin wins approval for gene therapy to treat hemophilia A

Why health workers in Gaza are injured or die at high rates

23andMe had bad news about my health. I wish a person had delivered it

Solve the antibiotic resistance crisis with preventive drugs

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

What to expect as Trump is arraigned on his Jan 6. indictment

New air purifier tech could be key to improving indoor air quality

Beam Therapeutics to lay off 20% of its staff, re

knowledge

Beam Therapeutics to lay off 20% of its staff, re

FDA warns J&J's Abiomed: We will regulate your software

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

No plane should take off without an EpiPen onboard

Will Ozempic

HHS leader on health, climate change and biopharma emissions

explore

focus

entertainment

focus